C.I. Rojas

Statistics

Publications

Citations

H-Index

Active since

2024

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

C.I. Rojas is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in metastatic cancer management, targeted cancer therapy, and non-small cell lung cancer immunotherapy.

Publications per year

2024–2025

Publications

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial

E. Felip, C.I. Rojas, M. Schenker et al. · Annals of Oncology · 2025 · 28 citations · Full text

Medicine, Oncology, Pharmacology +13

65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

Solange Peters, Daniel S.W. Tan, David E. Gerber et al. · Immuno-Oncology Technology · 2024 · 17 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

C.I. Rojas, Rosalyn A. Juergens, Adrian G. Sacher et al. · ESMO Open · 2024 · 13 citations · Full text

Pharmacy, Oncology, Pharmacology +16

1–3 of 3